Elferink JG, de Koster BM. The stimulation of human neutrophil migration by angiotensin I: its dependence on Caand the involvement of cyclic GMP[J]. Br J Pharmacol, 1997, 121(4): 643-648.
[2]
Gr？fe M, Auch-Schwelk W, Zakrzewicz A, et a1. AngiotensinⅡ-induced leukocytes adhesion on human coronary endothelial cells is mediated by E-selection[J]. Circ Res, 1997, 81(5): 804-811.
[3]
Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis[J]．Ann Intern Med，2001, 134(5): 426-427．
[ 2 ] Gan WQ, Man SF, Senthilselvan A, et al. Associasion between chronic obstructive pulmonary disease and systemic inflammation:a systematic review and a meta-analysis[J]. Thorax, 2004, 59(7): 574-580.
[6]
[ 3 ] Garrod R, Marshall J, Barley E, et al.The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD) [J]. Prim Care Respir J, 2007, 16(4): 236-240.
[7]
[ 4 ] Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxyl-methylglutaryl cocenzyme a reductase in pulmonary inflammation and host defense[J]. Am J Respir Crit Care Med, 2005, 171(6): 606-615.
[ 6 ] Ou XM, Wang BD, Wen FQ, et al. Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats[J]. Chin Med J (Engl), 2008, 121(17): 1680-1687.
[10]
[ 7 ] Ghavami S, Mutawe MM, Hauff K, et al. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome[J]. Biochim Biophys Acta, 2010, 1803(4): 452-467.
[11]
[ 8 ] Hothersall E, McSharry C, Tomo NC. Potential therapeutic role for statins in respiratory disease[J]. Thorox, 2006, 61(8): 729-734.
[12]
[ 9 ] Morimoto K, Janseen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease[J]. J Immunol, 2006, 176(12): 7657-7665.
[13]
Kim DY, Ryu SY, Lim JE, et al. Anti-inflammatory mechanism of simvastin in mouse allergic asthma model[J]. Eur J Pharmacol, 2007, 557(1): 76-86.
[14]
Cheelo M, Anselmi A, Spadaccio C, et al. simvastin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery[J]. Ann Thorac Surg, 2007, 83(4): 1374-1380.
[15]
Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin[J]. Am J Cardiol, 2008, 101(4): 530-535.
[16]
Kedissi JI, Younis WG, Chbier EA, et al. The use of statins and lung function incurrent and former smokers[J]. Chest, 2007, 132(6): 1764-1767.
[17]
Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function:VA Normative Aging Study[J]. Am J Respir Crit Care Med, 2007, 176(8): 742-747.
Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal preliferation and pulmonary hypertension in rats[J]. Am J Respir Crit Care Med, 2002, 166(10): 1403-1408.
[20]
Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J]. Circulation, 2003, 108(13): 1640-1645.
[21]
Syseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD[J]. Eur Respir J, 2007, 29(2): 279-283.
[22]
van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on comparison of those with versus without associated chronic obstructive pulmonary disease[J]. Am J Cardiol, 2008, 102(2): 192-196.
[23]
Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins,angiotensin-converting enzyme inhibitors,and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease[J]. J Am Coll Cardiol, 2006, 47(12): 2544-2560.
[24]
Phillips MI, Kagiyama S. Angiotensin I as a proinflammatory mediator[J]. Curr Opin lnvestig Drugs, 2002, 3(4): 569-577.
[25]
Suzuki Y, Ruiz-Ortega M, Lorenzo O, et a1. Inflammation and angiotensinⅡ[J]. Int J Biochem Cell Biol, 2003, 35(6): 881-900.
[26]
Ruiz-Ortega M, Lorenzo O, Suzuki Y, et a1. Prolnflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens, 2001, 10(3): 321-329.
[27]
Raiden S, Nahmod K, Namod V, et a1. Nonpeptide antagonists of AT1 receptor for angiotensin Ⅱ delay the onset of acute respiratory distress syndrome[J]. J Pharmacol Exp Ther, 2002, 303(1): 45-51.
[28]
Hernández-Presa MA, Bustos C, Ortego M, et a1. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent prolnflammatory factors but not of collagenI in a rabbit model of atherosclerosis[J]. Am J Pathol, 1998, 153(6): 1825-1837.
[29]
Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative efect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hyperholesterolemic and hypertensive patients[J]. J Cardiovasc Pharmacol, 2002, 40(1): 28-34.
[30]
Horiuchi M, Cui TX, Li Z, et a1. Fluvastatin enhances the inhibit-tory effects of a selective angiotensinⅡ Type 1 receptor blocker Valsartan On vascular neointimal formation[J]. Circulation, 2003, 107(1): 106-112.
[31]
Wassmann S, Laufs U, B？umer AT, et a1. Inhibition of geranylgeranylation reduces angiotensinⅡ mediated free radical production in vascular smooth muscle cells:involvement of angiotensin ATl receptor expression and Racl GTPase[J]. Mol Pharmacol, 2001, 59(3): 646-654.
